Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin. 2021; 71: 209-249
Annual report to the nation on the status of cancer, part I: national cancer statistics.Cancer. 2020; 126: 2225-2249
Body fatness and Cancer — viewpoint of the IARC working group.N. Engl. J. Med. 2016; 375: 794-798
- Onstad M.A.
- Schmandt R.E.
- Lu K.H.
Addressing the role of obesity in endometrial Cancer risk, prevention, and treatment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016; 34: 4225-4230
The growing burden of endometrial Cancer: a major racial disparity affecting black women.Cancer Epidemiol. Biomark. Prev. 2015; 24: 1407-1415
Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006.Br. J. Cancer. 2011; 104: 1505-1510
Unique molecular features in high-risk histology endometrial cancers.Cancers (Basel). 2019; 11
- Huijgens A.N.
- Mertens H.J.
Factors predicting recurrent endometrial cancer.Facts Views Vis Obgyn. 2013; 5: 179-186
Cancer statistics, 2021.CA Cancer J. Clin. 2021; 71: 7-33
Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer.Cancer. 2017; 123: 802-813
Interobserver agreement for mismatch repair protein immunohistochemistry in endometrial and nonserous, nonmucinous ovarian carcinomas.Am. J. Surg. Pathol. 2019; 43: 591-600
Incorporation of molecular characteristics into endometrial cancer management.Histopathology. 2020; 76: 52-63
Molecular classification of the PORTEC-3 trial for high-risk endometrial Cancer: impact on prognosis and benefit from adjuvant therapy.J. Clin. Oncol. 2020; 38: 3388-3397https://doi.org/10.1200/JCO.20.00549
Uterine Neoplasms v1. ()
Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.Ann. Oncol. 2013; 24 ()
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.Int. J. Gynecol. Cancer. 2021; 31: 12-39
Carboplatin and paclitaxel for advanced endometrial Cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology/GOG0209).J. Clin. Oncol. 2020; 38: 3841-3850
Second-line therapy for endometrial Cancer: the need for better options.J. Clin. Oncol. 2015; 33: 3535-3540
Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a gynecologic oncology group study.Gynecol. Oncol. 2003; 88: 277-281
A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the gynecologic oncology group.Gynecol. Oncol. 2008; 111: 22-26
Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P.J. Clin. Oncol. 2009; 27: 3104-3108
Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer.Int. J. Gynecol. Cancer. 2011; 21: 1446-1451
Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.Int. J. Gynecol. Cancer. 2013; 23: 929-934
Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a gynecologic oncology group study.J. Clin. Oncol. 2002; 20: 2360-2364
Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a gynecologic oncology group study.Gynecol. Oncol. 2006; 103: 523-526
Platinum rechallenge in second-line treatment for endometrial carcinoma.EJGO. 2019; 40: 963-969
Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: a retrospective study of the memorial Sloan Kettering Cancer center experience.Gynecol Oncol Rep. 2019; 28: 120-123
Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: the SGSG-012/GOTIC-004/intergroup study.Gynecol. Oncol. 2013; 131: 567-573
Treatment of Metastatic Endometrial Cancer.Aug 19. 2022
Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?.Cancer. 2010; 116: 5407-5414
Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin.Cancer Chemother. Pharmacol. 2011; 67: 829-835
What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/intergroup study.Cancer Chemother. Pharmacol. 2015; 76: 335-342
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease††These consensus statements were developed by the European Society for Medical Oncology (ESMO) and the European Society of Gynaecological Oncology (ESGO) and are published jointly in the Annals of Oncology and the International Journal of Gynecological Cancer. The two societies nominated participants who attended the consensus conference and co-authored the final manuscript.Annals of Oncology. 2019; 30: 672-705
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.Lancet Oncol. 2020; 21: 1353-1365
Lenvatinib plus Pembrolizumab in patients with advanced endometrial Cancer.J. Clin. Oncol. 2020; 38: 2981-2992
Lenvatinib plus Pembrolizumab for advanced endometrial Cancer.N. Engl. J. Med. 2022; 386: 437-448https://doi.org/10.1056/NEJMoa2108330
The history and future of targeting cyclin-dependent kinases in cancer therapy.Nat. Rev. Drug Discov. 2015; 14: 130-146
LBA28 a randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO/ENGOT-EN3 trial.Ann. Oncol. 2020; 31: S1160
- Konstantinopoulos P.A.
- E. L.
- Xiong N.
- et al.
Phase 2, two-stage study of letrozole and abemaciclib in estrogen receptor (ER) positive recurrent or metastatic endometrial cancer (EC).in: 2022 SGO Annual Meeting on Women’s Cancer. Phoenix,
Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers.ESMO Open. 2020; 5e000926
Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.Gynecol. Oncol. 2019; 152: 11-19
Frequent homologous recombination deficiency in high-grade endometrial carcinomas.Clin. Cancer Res. 2019; 25: 1087-1097
Homologous recombination repair mechanisms in serous endometrial Cancer.Cancers. 2021; 13: 254
- Konstantinopoulos P.A.
- et al.
Evaluation of treatment with Talazoparib and Avelumab in patients with recurrent mismatch repair proficient endometrial Cancer.JAMA Oncol. 2022; 8: 1317-1322
Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53.Gynecol. Oncol. 2013; 128: 461-469
Phase II study of the WEE1 inhibitor Adavosertib in recurrent uterine serous carcinoma.J. Clin. Oncol. 2021; 39: 1531-1539
Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas.Mod. Pathol. 2022; 35: 962-971https://doi.org/10.1038/s41379-021-00997-2
Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-Trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu.J. Clin. Oncol. 2018; 36: 2044-2051
Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-Trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis.Clin. Cancer Res. 2020; 26: 3928-3935
813P efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma (STATICE trial, NCCH1615): a multicenter, phase II clinical trial.Ann. Oncol. 2021; 32: S767
Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer.Ann. Oncol. 1996; 7: 861-863
A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer.Int. J. Clin. Oncol. 2008; 13: 62-65
A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a gynecologic oncology group study.J. Clin. Oncol. 1994; 12: 1408-1414
Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer: a retrospective analysis of patients treated at the Brazilian National Cancer Institute (INCA).Med. Oncol. 2018; 35: 20
Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a gynecologic oncology group study.Gynecol. Oncol. 2005; 98: 294-298
Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium.Cancer. 1994; 73: 1453-1455
Phase II evaluation of topotecan in carcinosarcoma of the uterus: a gynecologic oncology group study.Gynecol. Oncol. 2005; 98: 217-221
Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer.Gynecol. Oncol. 2015; 138: 18-23
A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the gynecologic oncology.Gynecol. Oncol. 2009; 115: 443-446
A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study.Gynecol. Oncol. 2011; 121: 118-121
Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial).Gynecol. Oncol. 2022; 165: 223-229
Phase II trial assessing niraparib with or without dostarlimab (anti-PD-1) in recurrent endometrial carcinoma.J. Clin. Oncol. 2021; 39: 5574